Transition to Rebif New Formulation
NCT00619307
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
117
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG:
Rebif New Formulation + prophylactic Ibuprofen
DRUG:
Rebif New Formulation + ibuprofen PRN
Sponsor
Merck KGaA, Darmstadt, Germany